Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
RELATED ARTICLES
-
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK600196.SHG - Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
